Nagi Bioscience raises 12.4MCHF Series A round
press release

Nagi Bioscience makes a strong debut at BIO International as part of the Innosuisse cohort for the Swiss Pavilion

About Nagi Bioscience

Founded in 2019, Nagi Bioscience is a spin-off of the École Polytechnique Fédérale de Lausanne (EPFL) pioneering the next-generation biological testing landscape for the past 10 years. With its innovative Organism-on-Chip technology, Nagi aims to revolutionize the way new substances are tested today through cutting-edge laboratory equipment that allows to unlock the full potential of small organisms. Under the motto in vivo testing at the in vitro scale, Nagi’s technologies are accelerating drug development pipelines and introducing new toxicology testing standards revolutionizing pharmaceutical, biotech, nutraceutical, cosmetic, and agro-chemical industries with fast, scalable, efficient, and ethical methods. The successful closure of its Series A funding round reflects Nagi’s potential to drive transformative change within the sector of alternatives to animal testing.

For more information, visit

About SydLab™ One

SydLab™ One is the first all-in-one laboratory technology for fully automated high-content screening on small organisms (C. elegans nematodes) to speed-up and de-risk your research and discovery efforts.
Based on Nagi’s patented Organism-on-Chip technology, SydLab™ One combines advanced microfluidic technology with cutting-edge robotics, AI, optics, and biology to automate the entire process of culture, treatment, imaging, and AI multi-phenotypic analysis of C. elegans within a single benchtop laboratory device.

For media inquiries, please contact:

Nagi Bioscience raises 12.4MCHF Series A round

Herminia Álvarez Sánchez

Marketing & Business Development Specialist

#inwormwetrust C. elegans blog